0001209191-19-022658.txt : 20190402 0001209191-19-022658.hdr.sgml : 20190402 20190402171917 ACCESSION NUMBER: 0001209191-19-022658 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190401 FILED AS OF DATE: 20190402 DATE AS OF CHANGE: 20190402 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schinazi Raymond F CENTRAL INDEX KEY: 0001397607 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38841 FILM NUMBER: 19726329 MAIL ADDRESS: STREET 1: 1860 MONTREAL ROAD CITY: TUCKER STATE: GA ZIP: 30084 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PRECISION BIOSCIENCES INC CENTRAL INDEX KEY: 0001357874 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 302 EAST PETTIGREW STREET STREET 2: SUITE A-100 CITY: DURHAM STATE: NC ZIP: 27701 BUSINESS PHONE: 919-314-5512 MAIL ADDRESS: STREET 1: 302 EAST PETTIGREW STREET STREET 2: SUITE A-100 CITY: DURHAM STATE: NC ZIP: 27701 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-04-01 0 0001357874 PRECISION BIOSCIENCES INC DTIL 0001397607 Schinazi Raymond F C/O PRECISION BIOSCIENCES, INC. 302 E. PETTIGREW STREET, SUITE A-100 DURHAM NC 27701 1 0 0 0 Common Stock 2019-04-01 4 C 0 36946 13.60 A 36946 I By RFS Partners, LP Common Stock 2019-04-01 4 C 0 56102 A 93048 I By RFS Partners, LP Convertible Promissory Note 13.60 2019-04-01 4 C 0 502466.00 D Common Stock 36946 0 I By RFS Partners, LP Series B Preferred Stock 2019-04-01 4 C 0 119761 D Common Stock 56102 0 I By RFS Partners, LP The securities reported herein are held of record by RFS Partners LP ("RFS"). RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein. The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO"). On March 1, 2019, RFS acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from the Issuer. Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO. /s/ Abid Ansari, Attorney-in-Fact for Raymond F. Schinazi 2019-04-02